Optimizing ICI and TKI Combinations + Dose Reductions

Medical experts explore dose reduction strategies, alternative therapies, and clinical pearls for optimizing health outcomes in renal cell carcinoma patients treated with immune checkpoint inhibitor and tyrosine kinase inhibitor combinations.

EP: 1.Clinical Case: Intermediate-Risk, Metastatic Clear Cell Renal Cell Carcinoma

EP: 2.Cosmic-313 and Alternate Lines of Therapy for Poor Risk Metastatic RCC

EP: 3.Risk Stratifying Patients with RCC: Making Informed Decisions

EP: 4.First-Line Immune Checkpoint Inhibitors for Poor Risk Metastatic RCC

EP: 5.Treatment Recommendations for a 59-Year-Old Woman with RCC

EP: 6.Monitoring Response in Immune Checkpoint Inhibitor-Based RCC Therapy

EP: 7.Patient Case: Workup and Imaging in RCC

EP: 8.Patient Case: A 61-Year-Old Patient with Indolent Metastatic ccRCC

EP: 9.First-Line Immune Checkpoint Inhibitor for Favorable-Risk Metastatic Renal Cell Carcinoma

Now Viewing

EP: 10.Optimizing ICI and TKI Combinations + Dose Reductions

EP: 11.Indolent Metastatic ccRCC Disease Progression and Guideline Updates

EP: 12.Third-Line Therapy for Patients with ccRCC

EP: 13.Patient Case: A 58-year-old Man With Hematuria and Abdominal Pain

EP: 14.First-Line ICI-Based Combinations for mRCC With Sarcomatoid Features

Recent Videos